NZD1.03 -0.0 -1.0%
Last Trade - 12:11am
| Market Cap | ÂŁ396.5m |
| Enterprise Value | ÂŁ383.4m |
| Revenue | ÂŁ2.85m |
| Position in Universe | 339th / 1832 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.90 | 4.98 | 3.21 | 3.40 | 3.82 | 4.37 | 10.9 | 28.6 | +18.1% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Pacific Edge Limited is a cancer diagnostics company. The Company develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The Company's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. It offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.
| Last Annual | March 31st, 2020 |
| Last Interim | September 30th, 2020 |
| Incorporated | February 27, 2001 |
| Public Since | February 12, 2003 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | New Zealand Stock Exchange |
| Shares in Issue | 724,763,562 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Centre for Innovation 87 St David St,PO Box 56, DUNEDIN, 9016, New Zealand |
| Web | https://www.pacificedgedx.com |
| Phone | +64 3 4795800 |
| Contact | () |
| Auditors | PricewaterhouseCoopers |
As of 12:11am, shares in Pacific Edge are trading at NZD1.03, giving the company a market capitalisation of ÂŁ396.5m. This share price information is delayed by 15 minutes.
Shares in Pacific Edge are currently trading at NZD1.03 and the price has moved by 0.713k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pacific Edge price has moved by 0.689k% over the past year.
Of the analysts with advisory recommendations for Pacific Edge, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Pacific Edge is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Pacific Edge is scheduled to issue upcoming financial results on the following dates:
Pacific Edge does not currently pay a dividend.
Pacific Edge does not currently pay a dividend.
Pacific Edge does not currently pay a dividend.
To buy shares in Pacific Edge you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Pacific Edge are currently trading at NZD1.03, giving the company a market capitalisation of ÂŁ396.5m.
Here are the trading details for Pacific Edge:
Based on an overall assessment of its quality, value and momentum, Pacific Edge is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Pacific Edge are currently priced at NZD1.03. At that level they are trading at 44.23% discount to the analyst consensus target price of 0.00.
Analysts covering Pacific Edge currently have a consensus Earnings Per Share (EPS) forecast of -0.018 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacific Edge. Over the past six months, the relative strength of its shares against the market has been 43.99%. At the current price of NZD1.03, shares in Pacific Edge are trading at 49.77% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Pacific Edge.
Pacific Edge's management team is headed by:
Here are the top five shareholders of Pacific Edge based on the size of their shareholding:
